Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02452190
Registration number
NCT02452190
Ethics application status
Date submitted
13/05/2015
Date registered
22/05/2015
Date last updated
9/11/2021
Titles & IDs
Public title
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
Query!
Scientific title
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Query!
Secondary ID [1]
0
0
2015-000865-29
Query!
Secondary ID [2]
0
0
C38072-AS-30025
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Asthma
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Asthma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Reslizumab
Treatment: Drugs - Placebo
Experimental: Reslizumab - Reslizumab
Placebo Comparator: Placebo - Matching Placebo
Treatment: Drugs: Reslizumab
Reslizumab will be administered subcutaneously in a dose of 110 mg every 4 weeks.
Treatment: Drugs: Placebo
Matching Placebo
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Clinical Asthma Exacerbations (CAEs) During 52 Weeks of Treatment
Query!
Assessment method [1]
0
0
A CAE was defined as a clinically-judged deterioration in asthma control, as determined by the investigator and as evidenced by new or worsening asthma signs or symptoms based on the participant's history, asthma control diary, physical examination, and/or ambulatory or clinic visit assessment of lung function and that resulted in a medical intervention, including at least 1 of the following: 1) use of systemic corticosteroids (oral or injection) or at least a doubling from a stable maintenance oral corticosteroid dose for at least 3 days; 2) asthma-specific hospital admission; 3) asthma-specific emergency department visit. Adjusted CAE rate and confidence intervals were based on Negative Binomial regression model adjusted for stratification factors. Results are presented as adjusted means. For this analysis, the offset variable is calculated as the logarithm of treatment duration minus the summed duration of exacerbations during the treatment period.
Query!
Timepoint [1]
0
0
Day 1 to Week 52
Query!
Secondary outcome [1]
0
0
Change From Baseline to Week 52 in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Query!
Assessment method [1]
0
0
Change in pre-bronchodilator FEV1 from baseline to week 52 is presented. FEV1 is a standard measurement of air movement in the lungs of participants with asthma obtained from pulmonary function tests. It is the volume of air expired in the first second of a forced expiration using a spirometer.
Analysis of the change from baseline to each visit was performed using a mixed effect model for repeated measures (MMRM) including fixed effects for treatment, visit, treatment by visit interaction, age group, blood eosinophil counts at enrollment, and sex, height and baseline value as covariates, and participant as a random effect.
Query!
Timepoint [1]
0
0
Baseline, Week 52
Query!
Secondary outcome [2]
0
0
Change From Baseline to Week 52 in Asthma Quality of Life Questionnaire for Participants 12 Years and Older (AQLQ+12) Score
Query!
Assessment method [2]
0
0
AQLQ is a 32-item instrument administered as a self-assessment. AQLQ+12 is a modified version of AQLQ developed to measure functional impairments of participants aged 12-70 years. It is divided into 4 domains: activity limitation, symptoms, emotional function, and environmental stimuli. Participants were asked to recall their experiences during the last 2 weeks and respond to each question on a 7-point scale (1=severe impairment, 7=no impairment), where higher scores indicated "better quality of life." Overall AQLQ+12 score is the mean of all 32 responses. Analysis of the change from baseline to each visit was performed using a MMRM including fixed effects for treatment, visit, treatment by visit interaction, age group, blood eosinophil counts at enrollment, and sex, height and baseline value as covariates, and participant as a random effect.
Query!
Timepoint [2]
0
0
Baseline, Week 52
Query!
Secondary outcome [3]
0
0
Change From Baseline to Week 52 in 6-item Asthma Control Questionnaire (ACQ-6) Score
Query!
Assessment method [3]
0
0
The ACQ-6 is a 6-item validated asthma assessment tool that has been widely used. Six questions are self-assessments (completed by the participant), 5 questions assessing asthma symptoms: night-time waking, symptoms on waking, activity limitation, shortness of breath, wheezing, and 1 question for short-acting bronchodilator use. Each item on the ACQ-6 has a possible score ranges from 0 to 6, and the total score is the mean of all responses. The total score ranging from 0-6 (0=totally controlled and 6=severely uncontrolled). A higher score indicated poorer asthma control. Analysis of the change from baseline to each visit was performed using a mixed effect model for repeated measures (MMRM) including fixed effects for treatment, visit, treatment by visit interaction, age group, blood eosinophil counts at enrollment, and sex, height and baseline value as covariates, and participant as a random effect.
Query!
Timepoint [3]
0
0
Baseline, Week 52
Query!
Secondary outcome [4]
0
0
Change From Baseline to Week 52 in Total Asthma Symptom Scores (Day and Night)
Query!
Assessment method [4]
0
0
Asthma symptoms were recorded by participant each day and night in an asthma control diary. Night score was assessed on a 5-point scale where 0=no symptoms, slept through night, to 4=bad night, no sleep. Day score was assessed on a 6-point scale where 0=very well, no symptoms, to 5= asthma very severe, unable to carry out daily activities. Total asthma symptom score was calculated by taking the sum of the night and day asthma symptom scores recorded, ranging from 0 (no symptom) to 9 (severe symptom). A lower symptom score indicated a better outcome. Analysis of the change from baseline to each visit was performed using a MMRM including fixed effects for treatment, visit, treatment by visit interaction, age group, blood eosinophil counts at enrollment, and sex, height and baseline value as covariates, and participant as a random effect.
Query!
Timepoint [4]
0
0
Baseline, Week 52
Query!
Secondary outcome [5]
0
0
Percentage of Asthma Control Days
Query!
Assessment method [5]
0
0
The percentage of asthma control days over 52 weeks of treatment is presented. An asthma control day was defined as a day on which the participant used less than or equal to 2 puffs of inhaled short-acting beta-agonist, had no nighttime awakenings, and experienced no asthma exacerbations. Analysis of the change from baseline to each visit was performed using a mixed effect MMRM including fixed effects for treatment, visit, treatment by visit interaction, age group, blood eosinophil counts at enrollment, and sex, height and baseline value as covariates, and participant as a random effect.
Query!
Timepoint [5]
0
0
Day 1 to Week 52
Query!
Secondary outcome [6]
0
0
Change From Baseline to Week 32 in St. George's Respiratory Questionnaire (SGRQ) Total Score
Query!
Assessment method [6]
0
0
The SGRQ is a 17-item questionnaire with 50 weighted responses. It provides a total score and three component scores: Symptoms (distress caused by respiratory symptoms), Activity (physical activities that cause or are limited by breathlessness), and Impacts (social and psychological effects of the disease). The total score and each of the SGRQ subscores are scored from 0 to 100 where 0 indicates best and 100 indicates worst health. An increase in score indicates worsening health. Analysis of the change from baseline to each visit was performed using a mixed effect model for repeated measures (MMRM) including fixed effects for treatment, visit, treatment by visit interaction, age group, blood eosinophil counts at enrollment, and sex, height and baseline value as covariates, and participant as a random effect.
Query!
Timepoint [6]
0
0
Baseline, Week 32
Query!
Secondary outcome [7]
0
0
Kaplan-Meier (K-M) Estimate of Probability (Percent [%]) of Not Experiencing a CAE by Week 52
Query!
Assessment method [7]
0
0
CAE was defined as a clinically judged deterioration in asthma control, as determined by the investigator and as evidenced by new or worsening asthma signs or symptoms based on the participant's history, asthma control diary, physical examination, and/or ambulatory or clinic visit assessment of lung function and that resulted in a medical intervention, including at least 1 of the following: 1) use of systemic corticosteroids (oral or injection) or at least a doubling from a stable maintenance oral corticosteroid dose for at least 3 days; 2) asthma-specific hospital admission; 3) asthma-specific emergency department visit.
The KM method was used to estimate and compare the distributions of time to first CAE between treatment groups. Participants without an event during the treatment period were censored at either the date of the end of treatment (Week 52) visit for participants who completed treatment or at the date of last dose (+4 weeks) for participants who discontinued early.
Query!
Timepoint [7]
0
0
Day 1 to Week 52
Query!
Secondary outcome [8]
0
0
Number of CAEs Requiring Hospitalization and/or Emergency Department Visits During 52 Weeks of Treatment
Query!
Assessment method [8]
0
0
A CAE was defined as a clinically judged deterioration in asthma control, as determined by the investigator and as evidenced by new or worsening asthma signs or symptoms based on the participant's history, asthma control diary, physical examination, and/or ambulatory or clinic visit assessment of lung function and that resulted in a medical intervention, including at least 1 of the following: 1) use of systemic corticosteroids (oral or injection) or at least a doubling from a stable maintenance oral corticosteroid dose for at least 3 days; 2) asthma-specific hospital admission; 3) asthma-specific emergency department visit. The frequency of CAEs over 52-week treatment period is expressed as adjusted CAEs rate in 52 weeks. Adjusted CAE rate and confidence intervals were based on Negative Binomial regression model adjusted for stratification factors (age group, blood eosinophil group) and number of prior exacerbations, and an offset variable.
Query!
Timepoint [8]
0
0
Day 1 to Week 52
Query!
Secondary outcome [9]
0
0
Number of Moderate Exacerbations During 52 Weeks of Treatment
Query!
Assessment method [9]
0
0
A moderate exacerbation was defined as a clinically judged deterioration in asthma control as determined by investigator and as evidenced by new or worsening asthma signs or symptoms based on the participant's history, asthma control diary, physical examination, and/or ambulatory or clinic visit assessment of lung function and that resulted in a medical intervention requiring additional asthma controller medication that was not a systemic corticosteroid and did not result in an asthma-specific hospitalization or emergency department visit (that is, a medical intervention that did not otherwise meet the criteria for primary endpoint). Frequency of moderate exacerbations over 52-week treatment period is expressed as adjusted exacerbation rate in 52 weeks. Adjusted exacerbation rate and confidence intervals were based on Negative Binomial regression model adjusted for stratification factors (age group, blood eosinophil group) and number of prior exacerbations, and an offset variable.
Query!
Timepoint [9]
0
0
Day 1 to Week 52
Query!
Eligibility
Key inclusion criteria
- Written informed consent is obtained.
- The participant is male or female, 12 years of age and older, with a diagnosis of
asthma.
- The participant has Forced Expiratory Volume in 1 Second (FEV1) reversibility
according to standard American Thoracic Society (ATS) or European Respiratory Society
(ERS) protocol.
- The participant has required an inhaled corticosteroid.
- The participant has required an additional asthma controller medication besides
inhaled corticosteroids.
- The participant has a history of asthma exacerbation.
- The participant must be willing and able to comply with study restrictions, perform
requisite procedures and remain at the clinic for the required duration during the
study period, and be willing to return to the clinic for the follow-up evaluation as
specified in this protocol.
- Additional criteria may apply, please contact the investigator for more
information
Query!
Minimum age
12
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- The participant has any clinically significant, uncontrolled medical condition
(treated or untreated) that would interfere with the study schedule or procedures,
interpretation of efficacy results, or compromise the patient's safety.
- The participant has another confounding underlying lung disorder
- The participant has a known hypereosinophilic syndrome.
- The participant has a diagnosis of malignancy within 5 years of the screening visit,
except for treated and cured non-melanoma skin cancers.
- The participant is a pregnant or lactating woman, or intends to become pregnant during
the study. Any woman becoming pregnant during the study will be withdrawn from the
study.
- The participant is a current smoker or has a smoking history.
- The participated in a clinical trial within 30 days or 5 half-lives of the
investigational drug before screening, whichever is longer.
- The participant was previously exposed to reslizumab.
- The participant has a history of an immunodeficiency disorder including human
immunodeficiency virus (HIV).
- The participant has current or suspected drug and alcohol abuse.
- The participant has an active helminthic parasitic infection or was treated for one
within 6 months of screening.
- The participant has a history of allergic reaction or hypersensitivity to any
component of the study drug.
- Additional criteria may apply, please contact the investigator for more
information
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
28/09/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
31/01/2018
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
468
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Teva Investigational Site 78085 - Bedford Park
Query!
Recruitment hospital [2]
0
0
Teva Investigational Site 78083 - Nedlands
Query!
Recruitment hospital [3]
0
0
Teva Investigational Site 78088 - Parkville
Query!
Recruitment hospital [4]
0
0
Teva Investigational Site 78087 - Sherwood
Query!
Recruitment hospital [5]
0
0
Teva Investigational Site 78084 - Woolloongabba
Query!
Recruitment postcode(s) [1]
0
0
5042 - Bedford Park
Query!
Recruitment postcode(s) [2]
0
0
6009 - Nedlands
Query!
Recruitment postcode(s) [3]
0
0
3052 - Parkville
Query!
Recruitment postcode(s) [4]
0
0
4075 - Sherwood
Query!
Recruitment postcode(s) [5]
0
0
- Woolloongabba
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Connecticut
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Florida
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Georgia
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Illinois
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Indiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kansas
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Kentucky
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Louisiana
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Massachusetts
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Mississippi
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Missouri
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Nebraska
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New Jersey
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
New York
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Ohio
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Oklahoma
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Oregon
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Pennsylvania
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Rhode Island
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Tennessee
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Texas
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Utah
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Virginia
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Washington
Query!
Country [30]
0
0
Argentina
Query!
State/province [30]
0
0
Buenos Aires
Query!
Country [31]
0
0
Argentina
Query!
State/province [31]
0
0
Cordoba
Query!
Country [32]
0
0
Argentina
Query!
State/province [32]
0
0
Lanus
Query!
Country [33]
0
0
Argentina
Query!
State/province [33]
0
0
Mar Del Plata
Query!
Country [34]
0
0
Argentina
Query!
State/province [34]
0
0
Mendoza
Query!
Country [35]
0
0
Argentina
Query!
State/province [35]
0
0
Rosario
Query!
Country [36]
0
0
Argentina
Query!
State/province [36]
0
0
San Miguel de Tucuman
Query!
Country [37]
0
0
Argentina
Query!
State/province [37]
0
0
San Rafael
Query!
Country [38]
0
0
Belgium
Query!
State/province [38]
0
0
Bruxelles
Query!
Country [39]
0
0
Belgium
Query!
State/province [39]
0
0
Erpent
Query!
Country [40]
0
0
Belgium
Query!
State/province [40]
0
0
Gent
Query!
Country [41]
0
0
Canada
Query!
State/province [41]
0
0
British Columbia
Query!
Country [42]
0
0
Canada
Query!
State/province [42]
0
0
Ontario
Query!
Country [43]
0
0
Canada
Query!
State/province [43]
0
0
Windsor
Query!
Country [44]
0
0
Czechia
Query!
State/province [44]
0
0
Jablonec nad Nisou
Query!
Country [45]
0
0
Czechia
Query!
State/province [45]
0
0
Jindrichuv Hradec
Query!
Country [46]
0
0
Czechia
Query!
State/province [46]
0
0
Tabor
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Strasbourg
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Toulouse
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Bad Worishofen
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Berlin
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Frankfurt am Main
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Frankfurt
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Hamburg
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Hannover
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Koblenz
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Leipzig
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Lubeck
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Mainz
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Witten
Query!
Country [60]
0
0
Hungary
Query!
State/province [60]
0
0
Balassagyarmat
Query!
Country [61]
0
0
Hungary
Query!
State/province [61]
0
0
Budapest
Query!
Country [62]
0
0
Hungary
Query!
State/province [62]
0
0
Csorna
Query!
Country [63]
0
0
Hungary
Query!
State/province [63]
0
0
Debrecen
Query!
Country [64]
0
0
Hungary
Query!
State/province [64]
0
0
Dombovar
Query!
Country [65]
0
0
Hungary
Query!
State/province [65]
0
0
Godollo
Query!
Country [66]
0
0
Hungary
Query!
State/province [66]
0
0
Gyor
Query!
Country [67]
0
0
Hungary
Query!
State/province [67]
0
0
Hajdunanas
Query!
Country [68]
0
0
Hungary
Query!
State/province [68]
0
0
Kaposvar
Query!
Country [69]
0
0
Hungary
Query!
State/province [69]
0
0
Kapuvar
Query!
Country [70]
0
0
Hungary
Query!
State/province [70]
0
0
Szazhalombatta
Query!
Country [71]
0
0
Hungary
Query!
State/province [71]
0
0
Szeged
Query!
Country [72]
0
0
Hungary
Query!
State/province [72]
0
0
Szigetvar
Query!
Country [73]
0
0
Hungary
Query!
State/province [73]
0
0
Szombathely
Query!
Country [74]
0
0
Hungary
Query!
State/province [74]
0
0
Veszprem
Query!
Country [75]
0
0
Israel
Query!
State/province [75]
0
0
Ashkelon
Query!
Country [76]
0
0
Israel
Query!
State/province [76]
0
0
Haifa
Query!
Country [77]
0
0
Israel
Query!
State/province [77]
0
0
Jerusalem
Query!
Country [78]
0
0
Israel
Query!
State/province [78]
0
0
Kfar Saba
Query!
Country [79]
0
0
Israel
Query!
State/province [79]
0
0
Petach Tikva
Query!
Country [80]
0
0
Israel
Query!
State/province [80]
0
0
Petah Tikva
Query!
Country [81]
0
0
Israel
Query!
State/province [81]
0
0
Ramat Gan
Query!
Country [82]
0
0
Israel
Query!
State/province [82]
0
0
Rehovot
Query!
Country [83]
0
0
Japan
Query!
State/province [83]
0
0
Amagasaki
Query!
Country [84]
0
0
Japan
Query!
State/province [84]
0
0
Ginowan
Query!
Country [85]
0
0
Japan
Query!
State/province [85]
0
0
Hakodate
Query!
Country [86]
0
0
Japan
Query!
State/province [86]
0
0
Hiroshima
Query!
Country [87]
0
0
Japan
Query!
State/province [87]
0
0
Kanazawa-shi
Query!
Country [88]
0
0
Japan
Query!
State/province [88]
0
0
Kishiwada-shi
Query!
Country [89]
0
0
Japan
Query!
State/province [89]
0
0
Kobe
Query!
Country [90]
0
0
Japan
Query!
State/province [90]
0
0
Kodaira
Query!
Country [91]
0
0
Japan
Query!
State/province [91]
0
0
Kumamoto
Query!
Country [92]
0
0
Japan
Query!
State/province [92]
0
0
Mizunami-shi
Query!
Country [93]
0
0
Japan
Query!
State/province [93]
0
0
Sagamihara
Query!
Country [94]
0
0
Japan
Query!
State/province [94]
0
0
Tokyo
Query!
Country [95]
0
0
Japan
Query!
State/province [95]
0
0
Toyama-shi
Query!
Country [96]
0
0
Japan
Query!
State/province [96]
0
0
Toyama
Query!
Country [97]
0
0
Japan
Query!
State/province [97]
0
0
Toyoake-shi
Query!
Country [98]
0
0
Japan
Query!
State/province [98]
0
0
Yokohama-shi
Query!
Country [99]
0
0
Korea, Republic of
Query!
State/province [99]
0
0
Bucheon
Query!
Country [100]
0
0
Korea, Republic of
Query!
State/province [100]
0
0
Seoul
Query!
Country [101]
0
0
Mexico
Query!
State/province [101]
0
0
Guadalajara
Query!
Country [102]
0
0
Mexico
Query!
State/province [102]
0
0
Monterrey
Query!
Country [103]
0
0
Mexico
Query!
State/province [103]
0
0
Zapopan
Query!
Country [104]
0
0
New Zealand
Query!
State/province [104]
0
0
Auckland
Query!
Country [105]
0
0
Poland
Query!
State/province [105]
0
0
Bialystok
Query!
Country [106]
0
0
Poland
Query!
State/province [106]
0
0
Gdansk
Query!
Country [107]
0
0
Poland
Query!
State/province [107]
0
0
Krakow
Query!
Country [108]
0
0
Poland
Query!
State/province [108]
0
0
Lodz
Query!
Country [109]
0
0
Poland
Query!
State/province [109]
0
0
Poznan
Query!
Country [110]
0
0
Poland
Query!
State/province [110]
0
0
Tarnow
Query!
Country [111]
0
0
Romania
Query!
State/province [111]
0
0
Brasov
Query!
Country [112]
0
0
Romania
Query!
State/province [112]
0
0
Bucharest
Query!
Country [113]
0
0
Romania
Query!
State/province [113]
0
0
Cluj-Napoca
Query!
Country [114]
0
0
Romania
Query!
State/province [114]
0
0
Deva
Query!
Country [115]
0
0
Romania
Query!
State/province [115]
0
0
Targu Mures
Query!
Country [116]
0
0
Romania
Query!
State/province [116]
0
0
Timisoara
Query!
Country [117]
0
0
Russian Federation
Query!
State/province [117]
0
0
Barnaul
Query!
Country [118]
0
0
Russian Federation
Query!
State/province [118]
0
0
Kemerovo
Query!
Country [119]
0
0
Russian Federation
Query!
State/province [119]
0
0
Moscow
Query!
Country [120]
0
0
Russian Federation
Query!
State/province [120]
0
0
Novosibirsk
Query!
Country [121]
0
0
Russian Federation
Query!
State/province [121]
0
0
Saint Petersburg
Query!
Country [122]
0
0
Russian Federation
Query!
State/province [122]
0
0
St. Petersburg
Query!
Country [123]
0
0
Russian Federation
Query!
State/province [123]
0
0
Tomsk
Query!
Country [124]
0
0
South Africa
Query!
State/province [124]
0
0
Benoni
Query!
Country [125]
0
0
South Africa
Query!
State/province [125]
0
0
Bloemfontein
Query!
Country [126]
0
0
South Africa
Query!
State/province [126]
0
0
Cape Town
Query!
Country [127]
0
0
South Africa
Query!
State/province [127]
0
0
Durban
Query!
Country [128]
0
0
Spain
Query!
State/province [128]
0
0
Barcelona
Query!
Country [129]
0
0
Spain
Query!
State/province [129]
0
0
Esplugues de Llobregat
Query!
Country [130]
0
0
Spain
Query!
State/province [130]
0
0
Girona
Query!
Country [131]
0
0
Spain
Query!
State/province [131]
0
0
Vitoria-Gasteiz
Query!
Country [132]
0
0
Turkey
Query!
State/province [132]
0
0
Ankara
Query!
Country [133]
0
0
Turkey
Query!
State/province [133]
0
0
Izmir
Query!
Country [134]
0
0
Turkey
Query!
State/province [134]
0
0
Kocaeli
Query!
Country [135]
0
0
Turkey
Query!
State/province [135]
0
0
Konya
Query!
Country [136]
0
0
Turkey
Query!
State/province [136]
0
0
Mersin
Query!
Country [137]
0
0
Ukraine
Query!
State/province [137]
0
0
Chernivtsi
Query!
Country [138]
0
0
Ukraine
Query!
State/province [138]
0
0
Dnipropetrovsk
Query!
Country [139]
0
0
Ukraine
Query!
State/province [139]
0
0
Ivano-Frankivsk
Query!
Country [140]
0
0
Ukraine
Query!
State/province [140]
0
0
Kharkiv
Query!
Country [141]
0
0
Ukraine
Query!
State/province [141]
0
0
Kremenchuk
Query!
Country [142]
0
0
Ukraine
Query!
State/province [142]
0
0
Kryvyi Rih
Query!
Country [143]
0
0
Ukraine
Query!
State/province [143]
0
0
Kyiv
Query!
Country [144]
0
0
Ukraine
Query!
State/province [144]
0
0
Sumy
Query!
Country [145]
0
0
Ukraine
Query!
State/province [145]
0
0
Vinnytsia
Query!
Country [146]
0
0
Ukraine
Query!
State/province [146]
0
0
Vinnytsya
Query!
Country [147]
0
0
Ukraine
Query!
State/province [147]
0
0
Zaporizhzhya
Query!
Country [148]
0
0
Ukraine
Query!
State/province [148]
0
0
Zhaporizhzhya
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Teva Branded Pharmaceutical Products R&D, Inc.
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
PPD
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective of this study is to determine the effect of reslizumab (110 mg)
administered subcutaneously every 4 weeks on clinical asthma exacerbations in adults and
adolescents with asthma and elevated blood eosinophils who are inadequately controlled on
standard-of-care asthma therapy.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02452190
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Teva Medical Expert, MD
Query!
Address
0
0
Teva Branded Pharmaceutical Products R&D, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02452190
Download to PDF